ANORO ELLIPTA
LAMALABA DPI
Umeclidinium / Vilanterol · GlaxoSmithKline
Active Medication & Mechanism
- Umeclidinium bromide LAMA62.5 mcg per blister
Long-acting muscarinic antagonist (anticholinergic). Blocks M3 muscarinic receptors on airway smooth muscle, inhibiting acetylcholine-mediated bronchoconstriction.
- Vilanterol trifenatate LABA25 mcg per blister
Long-acting beta2-adrenergic agonist. Stimulates beta2-receptors producing sustained bronchodilation (≥24 hours at once-daily dosing).
FDA-Approved Dosing by Indication
// approval varies by strength + age COPD
1/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| 62.5/25 mcg | Adults (≥18 years) | 1 inhalation once daily Long-term, once-daily maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema. | 62.5/25 mcg | FDA Approved |
Asthma
0/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| Any strength | All patients | — | — | Not Approved Anoro Ellipta is NOT indicated for asthma. LABA without ICS in asthma increases risk of serious asthma-related events. |
Acute Use
0/1 approved regimens| Strength | Population | Dose & Frequency | Total Daily | Status |
|---|---|---|---|---|
| Any strength | Acute bronchospasm / rescue | — | — | Not Approved Not indicated for relief of acute bronchospasm. Use a SABA. |